ReviewNature medicine2023
Recent successes in heart failure treatment.
Review in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients.ESC heart failure · 2025Trial
- The emerging roles of small nucleolar RNAs, piwi-interacting RNAs, tRNA-derived small RNAs, and circular RNAs in the regulation of cardiac hypertrophy, ischemic heart disease, and heart failure.Genes & diseases · 2026Review
- Exploration of the Pathogenesis and Treatment of Heart Failure.Reviews in cardiovascular medicine · 2026Review
- Digital heart failure management: Insights from the COPILOT study.Heart failure reviews · 2026Review
- Systematic analyses uncover plasma proteins linked to incident cardiovascular diseases.Protein & cell · 2026Article
- Interleukin-6 blockade modulates monocyte recruitment to protect against diastolic dysfunction associated with inflammatory arthritis.Arthritis research & therapy · 2026Article
- Proteomics risk scores and mortality in heart failure: Generalizability across populations.PloS one · 2026Article
- Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications.Frontiers in pharmacology · 2026Review
- Novel echocardiographic tools for predicting a good response to cardiac resynchronization therapy: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry.European journal of heart failure · 2025Observational
- Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF guidelines.ESC heart failure · 2025Article
- Cardiac repair and regeneration: cell therapy, in vivo reprogramming, and the promise of extracellular vesicles.Experimental & molecular medicine · 2025Review
- Clinical and echocardiographic outcomes of sync-atrioventricular versus nominal optimization in correlation with QRS narrowing among CRT patients.BMC cardiovascular disorders · 2025Article
- Molecular Phenogroups in Heart Failure: Large-Scale Proteomics in a Population-Based Cohort.Circulation. Genomic and precision medicine · 2025Article
- Current Treatment of Heart Failure with Preserved Ejection Fraction.Journal of clinical medicine · 2025Review
- Clinical Phenotypes in Relation to Outcomes in Heart Failure Patients With Cardiac Resynchronization Therapy and Defibrillators (CRT-D): An Unsupervised Cluster Analysis.Journal of cardiovascular electrophysiology · 2025Observational
- Artesunate Inhibits Neointimal Hyperplasia by Promoting IRF4 Associated Macrophage Polarization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Contemporary Profile and In-Hospital Outcomes of Decompensated Heart Failure in a Semi-Rural Setting in Cameroon: The Buea Heart Study.Global heart · 2025Observational
- A Cross-talk between Nanomedicines and Cardiac Complications: Comprehensive View.Current pharmaceutical design · 2025Review
- The order of things: phosphate release or the power stroke, which does actomyosin do first?Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 5 countries.
Funding
Abstract
Remarkable recent advances have revolutionized the field of heart failure. Survival has improved among individuals with heart failure and a reduced ejection fraction and for the first time, new therapies have been shown to improve outcomes across the entire ejection fraction spectrum of heart failure. Great strides have been taken in the treatment of specific cardiomyopathies such as cardiac amyloidosis and hypertrophic cardiomyopathy, whereby conditions once considered incurable can now be effectively managed with novel genetic and molecular approaches. Yet there remain substantial residual unmet needs in heart failure. The translation of successful clinical trials to improved patient outcomes is limited by large gaps in implementation of care, widespread lack of disease awareness and poor understanding of the socioeconomic determinants of outcomes and how to address disparities. Ongoing clinical trials, advances in phenotype segmentation for precision medicine and the rise in technology solutions all offer hope for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.